Inhibition of profibrotic microRNA-21 affects platelets and their releasate

Fibrosis is a major contributor to organ disease for which no specific therapy is available. MicroRNA-21 (miR-21) has been implicated in the fibrogenetic response, and inhibitors of miR-21 are currently undergoing clinical trials. Here, we explore how miR-21 inhibition may attenuate fibrosis using a...

Descripción completa

Detalles Bibliográficos
Autores principales: Barwari, Temo, Eminaga, Seda, Mayr, Ursula, Lu, Ruifang, Armstrong, Paul C., Chan, Melissa V., Sahraei, Mahnaz, Fernández-Fuertes, Marta, Moreau, Thomas, Barallobre-Barreiro, Javier, Lynch, Marc, Yin, Xiaoke, Schulte, Christian, Baig, Ferheen, Pechlaner, Raimund, Langley, Sarah R., Zampetaki, Anna, Santer, Peter, Weger, Martin, Plasenzotti, Roberto, Schosserer, Markus, Grillari, Johannes, Kiechl, Stefan, Willeit, Johann, Shah, Ajay M., Ghevaert, Cedric, Warner, Timothy D., Fernández-Hernando, Carlos, Suárez, Yajaira, Mayr, Manuel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Clinical Investigation 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6238735/
https://www.ncbi.nlm.nih.gov/pubmed/30385722
http://dx.doi.org/10.1172/jci.insight.123335

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6238735/
https://www.ncbi.nlm.nih.gov/pubmed/30385722
http://dx.doi.org/10.1172/jci.insight.123335

Ejemplares similares